ArticleFrontiers in immunology2018

What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?

Theodoros EleftheriadisPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.